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1. Introduction
1.1. Perioperative management of antiplatelet
and anticoagulation therapy
Over the last years implanting physicians are frequently forced to manage perioperative sit‐
uation with increased bleeding risk due to anticoagulation (oral or intravenous) or dual anti‐
platelet therapy. Large number of patients have indication for long term use of oral
anticoagulation because of atrial fibrillation, prosthetic heart valves, anamnestic cerebrovas‐
cular accident or recurrent venous thromboembolism. On the other hand an increasing
number of patients have indication for dual antiplatelet therapy (DAPT) - mainly after coro‐
nary artery interventions. There is an increased need for a standardized perioperative man‐
agement by either postponing the procedure (if clinically possible), bridging or pausing the
therapy or taking the risk of a bleeding complication if inevitable. To help the implanting
physician with a reasonable decision, there are guidelines offered by the large cardiology so‐
cieties [1-4] concerning the management of patients with AF, as well as recent publications
dealing with this increasing challenge [5-7].
1.2. Antiplatelet therapy
Antiplatelet therapy is usually indicated after coronary artery interventions, myocardial in‐
farction as well as extracardial indications including cerebral infarction or peripheral artery
disease. Following coronary intervention the need for dual antiplatelet therapy usually is
temporally, the duration of therapy depending on the type of stent (bare metal Stent /BMS/
vs. drug eluting stent /DES/) as well as on the stent position and implant indication (acute
coronary syndrome vs. elective angioplasty). Following this time period most patients will
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be put on aspirin therapy lifelong. Shortening the initially recommended time period of
DAPT is highly discouraged due to high risk of stent thrombosis. On the other hand most
PM and numerous ICD implants should not be postponed because of a potential or evident
risk of syncope, asystoly or sudden cardiac death.
A review of recent studies shows interesting and relevant results concerning device implan‐
tations under DAPT. Patients underwent device implantation under DAPT (ASA and clopi‐
dogrel) suffered the highest rate of pocket hematomas and bleeding complications when
compared to patients with ASA alone or oral anticoagulation. The risk of pocket hematoma
in patients implanted under DAPT may as high as 20% in a smaller study (200 patients 10%
with DAPT) [6]. Tompkins et al. retrospectively analyzed 1388 device implantations includ‐
ing 139 patients with DAPT, they found a 4-fold increased risk of bleeding complications
compared to controls (7.2% vs. 1.6%) [7]. In this study patients receiving only ASA therapy
had a bleeding risk more than 2-fold (3.9% vs. 1.6%) showing a trend to significance
(p=0.078). Kutinsky et al. collected prospectively the data of 935 PM and ICD implantations
concerning pocket hematomas. They described an overall bleeding risk of 9.5%, which was
significantly increased in those on clopidogrel therapy (18.3%) [8]. Data concerning the
“new” antiplatelet agents ticagrelor and prasugrel in device implantations are missing. Pra‐
sugrel showed to have a higher bleeding risk in the interventional and CABG parts of the
TRITON-TIMI38 trial [9-11]. To which extend this may be extrapolated to device implanta‐
tion is questionable. Ticagrelor showed a comparable bleeding risk to clopidogrel in the
PLATO Trial [12, 13]. Again there is no explicit data on the risk of bleeding and hematoma
in pacemaker or ICD implant procedures.
1.3. Oral anticoagulants
Besides antiplatelet therapy as concomitant treatment in cardiovascular patients there are
many treated with oral  anticoagulants  (OAC) /  vitamin K antagonists  (VKA) needing a
device implantation or revision. In the last years new drugs evolved in this field of anti‐
coagulation with broad indication spectrum reaching from deep venous thrombosis pro‐
phylaxis and therapy up to the prevention of cardio-embolic events in atrial  fibrillation.
In contrast to the described dual antiplatelet therapy oral anticoagulation therapy for ex‐
ample  in  AF and after  mechanical  heart  valve  replacement  is  a  lifelong therapy with a
constant risk of thromboembolic and bleeding events. Thus postponing implantation pro‐
cedure  -  even  if  clinically  possible  -  is  of  little  help.  Three  options  arise  when  dealing
with patients on oral anticoagulation: 1.  Pausing OAC and bridging with unfractionated
(UFH) or low molecular weight (LMWH) heparin, 2. Continue OAC and perform the im‐
plantation at a moderate INR (e.g. 1.5-2.0) if possible, 3. Pausing completely and reinitiat‐
ing 3-5 days post implantation. In patients with the need for anticoagulation therapy the
risk of thromboembolic events may be categorized into low, moderate or high by adopt‐
ing and expanding the CHA2DS2-VASc-Score (table 1). The action taken should be adopt‐
ed to this risk (table 2) [14].
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Risk factor Score
Congestive heart
failure/LV-dysfunction 1
Hypertension 1
Age 65-74 years 1
Age ≥ 75 years 2
Diabetes mellitus 1
Stroke/TIA/thrombo-
embolism 2
Vascular disease 1
Sex (female) 1
Total Maximum 9
Table 1. The CHA2DS2-VASc-Score
Score Risk
0 0
1 1.3
2 2.2
3 3.2
4 4.0
5 6.7
6 9.8
7 9.6
8 6.7
9 15.2
Table 2. Adjusted stroke rate according to the CHA2DS2-VASc-Score
There are several publications dealing with device implantation in anticoagulated patients.
Most of them evaluate the use/benefit of perioperative bridging therapy. Giudici et al re‐
ported a series of 1025 implants including 470 oral anticoagulated patients with a mean INR
of 2.6 (±1). The rate of pocket hematoma was not significantly different between the two
groups (OAC 2.6%, Controls 2.2%) [15]. Wiegand et al. reported their analysis of predictors
of pocket hematoma in 3164 PM/ICD implants and generator exchanges [16]. Besides a de‐
scribed risk of hematoma formation of 3.1% under ASA and 21.7% under DAPT, a higher
risk of hematoma formation could be found in patients were OAC therapy was bridged with
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UFH perioperative. In this study two postoperative regiments were compared. One with a
bolus of heparin immediate at the end of the procedure (2.500 IU to 5000 IU) followed by
continuous infusion (target aPTT from 40-60s). The other group was started on continuous
heparin infusion without a bolus within 12h post implantation with the same target aPTT.
The risk of pocket hematoma was 28.1% in the bolus and 12% in the standard group. One
further study reports data of a “head to head” comparison in CRT-implants between pa‐
tients on OAC having an INR 2-3 perioperative, a second group having heparin bridging
therapy and a third – control – group including patients where OAC was simply stopped for
4 days. It showed again that the incidence of pocket hematomas were significantly increased
in patients where heparin bridging was performed: 20.7% vs. 5.0% in the OAC group and
4.1% in controls (p=0.03). Hematomas were responsible for longer in hospital stays (controls:
1.6 ± 1.6; warfarin group: 2.9 ± 2.7; bridging 3.7 ± 3.2; p < 0.001) [17].
It should be noted that the data of all the reported studies showed different rates of hemato‐
ma formation with and without anticoagulation or bridging therapy but no significantly dif‐
ferent rate in the occurrence of thromboembolic events were described.
Furthermore, new anticoagulant agents became available recently: the oral direct thrombi‐
ninhibitor dabigatran and the oral Factor Xa inhibitor rivaroxaban, both approved to pre‐
vent thromboembolic events in patients with non valvular atrial fibrillation as well as to
prevent post surgery venous thrombosis. There are only limited data on bleeding complica‐
tions in pacemaker and defibrillator implantation under therapy with one of these two new
approved drugs. Data from the RELY trial (dabigatran) in patients (4591 patients) with AF
and the need for an interventional procedure, including pacemaker/defibrillator implanta‐
tion (10.3%) showed no significantly different risks for major bleeding when compared with
warfarin (dabigatran 110 mg 3.8% or dabigatran 150 mg 5.1% or warfarin 4.6%) [18]. The
median dabigatran discontinuation was 49 hours (25-85) ahead of the procedure compared
to 114 hours (87-144) in patients on OAC. One study was evaluating the risk of major bleed‐
ing events after total hip or total knee arthroplasty in patients concomitantly treated with
NSAIDS or ASA and dabigatran (2x110mg or 1x150mg daily) [19]. In this study no differ‐
ence in major bleeding events could be observed, neither between dabigatran and enoxapar‐
in treated patients nor between concomitantly treated patients.
A recent metaanalysis by Bernard et al. [20] showed an overall incidence of bleeding compli‐
cations of 4.6% ranging from 2.2% in patients without any anticoagulation/antiplatelet thera‐
py up to 14.6% in patients receiving a heparin bridging strategy. Calculated odds ratios
compared to the no therapy group was 8.3 (95% CI 5.5-12.9) for heparin bridging strategy,
5.0 (95% CI 3.0-8.3) for dual antiplatelet therapy and 1.6 (95% CI 0.9-2.6) with continued oral
anticoagulation. This again contributes to the idea that bridging therapy (despite high risk
patients) is maybe not the best way to go.
1.4. Conclusion / recommendation
In our institution considering the above mentioned we decided to adopt a recommendation
from Korantzopoulos et al. modified algorithm [21]. In patients undergoing generator re‐
placement or Loop-Recorder implantation we continue the actual therapy, antiplatelet as
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well as anticoagulation, aiming to an INR of max. 2.5. All new implantations, revisions or
upgrades needing vascular access are managed differently – according to our flow chart
(Scheme 1 - adopted and modified after Hofmeister and Korantzopoulos [14, 21]). If dual an‐
tiplatelet therapy is present we try to postpone the procedure, according to current guide‐
lines depending on the indication for DAPT. The time with the need for DAPT depends on
the used Stent(s) as well as the anatomic position and the indication itself (ACS vs. elective).
In general DAPT is mandatory for at least 6 month, in patients after ACS as well as in pa‐
tients with a drug eluting stent (DES). After non DES implantation DAPT has to be adminis‐
tered for at least 4 weeks. If postponing is impossible the implant-procedure would be
performed under dual antiplatelet therapy and wide precautions. Single antiplatelet therapy
would be continued.
In patients under oral anticoagulation therapy we apply table 1, 2 and 3 to estimate the pa‐
tient´s risk for thromboembolic events. Patients with low risk will be operated with a break
of OAC and an INR of up to 2.0. OAC will be resumed after 48h with the maintenance dose.
Patients with medium risk will be operated with continued OAC and an INR of 2.0 2.5. High
risk patients according to table 3 will be discussed and depending on the procedure either
Scheme 1.
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be operated with an INR close to 2.5 or heparin bridging therapy. We do not perform bridg‐
ing with any type of heparin as a routine protocol. Oral Anticoagulation should be stopped
approximately 3-5 days before the procedure, depending on the used substance as well the
individual maintenance dose. Local haemostiptics or drainage will be used by the judgment
of the operator.
Thromboembolic risk assessment in patients on oral anticoagulation
Low thromboembolic risk (<5%/year) Medium thromboembolic risk(5-10%/year)
High thromboembolic risk (>10%/
year)
AF patients with CHA2DS2-VASc-Score
0-2 (but no TIA/CVA)
Mechanical aortic valves (> 3 months)
Post venous thromboembolism (>12
month)
AF patients with CHA2DS2-VASc-Score
3-5
Mechanical aortic valves + AF
Malignancy ass. venous
thromboembolism
Multiple or current thromboembolism
Valve repair/-exchange (<3months)
AF patients with CHA2DS2-VASc-Score
5-6 (or TIA/CVA <3months)
Mechanical mitral valves
Mechanical aortic valves + AF
(CHA2DS2-VASc ≥2)
Mechanical aortic valves (older
models)
Known thrombophilic disorder
LV-thrombus
Table 3. Relative Risk assessment of perioperative thromboembolic events without anticoagulation therapy. Modified
after Douketis JD, et al (2008) The perioperative management of antithrombotic therapy (ACCP Evidence-based
clinical practice guidelines, 8th Edition). Chest 133:299–339 and De Caterina R, Husted S, Wallentin L et al (2007)
Anticoagulants in heart disease: current status and perspectives. Eur Heart J 28:880–913
2. Perioperative antibiotic therapy
2.1. Introduction
Since the beginning of cardiac implantable electronic devices (CIED) prevention of device
infection is a serious issue and is under permanent discussion [22-24].
Despite “optimal implantation procedure” concerning optimal sterility and hygienic con‐
ditions  in  terms  of  materials,  implant  room  and  process,  there  are  several  factors  that
pose a  higher  risk for  CIED infections:  device/pocket  revision,  use  of  temporary pacing
leads before placement of  the permanent device,  central  venous catheters,  longer opera‐
tive  time  and  operator  inexperience,  development  of  postoperative  pocket  hematoma,
diabetes  mellitus,  long-term  use  of  corticosteroids  and  other  immunosuppressive  drugs
and seperated focus of primary infection [25]. The use of perioperative antibiotics or the
therapy of  choice,  as  well  as  necessity  and effect  of  flushing the wound with antiinfec‐
tive detergents is under debate [26, 27]. There are newly developed antimicrobial device
coatings which are not yet available [28, 29].
Described rates of implant related device infections in published studies have a wide range
reaching from 0.13% to 19.9% with 0.5% of the patients developing endocarditis or sepsis as
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a major complication [24, 30]. In addition to the severe or even lethal complication there is
also an impact on health economics with estimated costs of up to 50.000$ per case [31, 32].
The daily routine of perioperative antibiotic administration to prevent infections of CIED is
highly variable in terms of agents and dosage. It is generally accepted that a reduction of
device infections can be achieved by this approach [33]. Regiments based on vancomycin,
imipenem or cephazolin administered either perioperative as single shot or up to 3 days are
known. In terms of evidence based medicine there are just 7 trials dealing with periopera‐
tive antibiotics in CIEDS up to 2009 [27, 30, 34]. They were consisted of small number of pa‐
tients with very variable designs in terms of follow up duration, inclusion criteria, used
antibiotic agent and definition of events. Thus varying results were reported and a definite
conclusion could hardly be found. Four of those trials described a benefit in terms of reduc‐
tion of device/system infections. Three did not describe any difference, however, in one
study there was no infection at all in the included 106 patients [35]. Those trials were mainly
conducted in the 1980´s – another limitation since implanted systems (generators and leads)
as well as implant techniques underwent marked developments in the last 3 decades.
The most recent and relevant study was a double-blinded randomized trial by Oliveira et al.
in 2009 [36]. In this study 649 consecutive ICD and pacemaker patients (first implant and
generator replacement) were included and followed (fixed schedule for 6 month and addi‐
tionally when clinically indicated). Randomization was made to either 1g of cephazolin or
placebo directly prior operation. Allergic patients were excluded. The primary endpoint was
the occurrence of infection, classified being one of the following: superficial, pocket or sys‐
temic infection. The two groups were balanced and no differences concerning the known
risk factors for CIED infections were present. The study was interrupted after 26.5 month by
the safety committee because of significant differences in the primary endpoint. CIED relat‐
ed infections occurred in 0.64% in the cephazolin group and 3.28% in the placebo group
(p=0.016). The 13 patients that developed infections showed the typically germs all from the
Staphylococcus-family. The time until infection after implantation was 11-33 days without a
difference between the cephazolin and the placebo group. The multivariate analysis identi‐
fied pocket hematoma and lack of antibiotic prophylaxis as independent risk factors for any
kind of infection. Odds ratios were not calculated.
Based on the results of this study as well as previously published non randomized data
antibiotic prophylaxis should be performed in any device related operation (implantation
as  well  as  generator  replacement).  In  our  institution cephazolin  is  administered -  being
the  only  evidence  based  antibiotic  drug  until  now.  In  case  of  known  allergy  against
cephazolin  a  single  shot  of  1g  vancomycin  seems  the  most  appropriate  alternative  as
most common species in CIED infection are staphylococci  or streptococci  [37,  38].  If  the
implanting  hospital  has  a  high  prevalence  of  methicilin-resistant  staphylococci  (MRSA)
vancomycin should be considered to be the first choice [33].  Some authors argue that in
some regions with a very high prevalence of MRSA vancomycin should be even general‐
ly the first choice, however, this is not evidence based and should be considered careful‐
ly together with the local infectologist [33].
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An interesting, newly developed approach of device coatings seems to be able to control
local  bacterial  growth and thus is  supposed to be able to prevent system infections [28,
29]. The study by Matl et al.  describes the use of gentamycin and teicoplanin in a lipid-
based drug delivery-system which was able to deliver high local concentrations over 96h
and inhibit completely the growth of S. aureaus in vivo [28]. Wong et al. published data
on  a  dual  layer  device  coating,  consisting  of  gentamycin  to  control  local  colonization/
infection and diclofenac to control local inflammation due to tissue injury on top of a mi‐
crobicidal base film [29]. In vitro they could show excellent results in terms of S. aureus
control  (figure  1).  No data  on extended in  vivo use  of  any coating is  yet  available  but
the idea and techniques are promising.
Figure 1. Media-borne assay with S. aureus with increasing time of incubation in bacterial solution; top row shows
bare substrates completely colonized by bacteria (light beige colored dots); bottom row shows (DMLPEI/PAA)10 films
with degradable top films completely eroded with no sign of colonization by bacteria (black colored substrate). From
Wong et al., Journal of the American Chemical Society 2010.
3. Conclusion / recommendation
Concerning  the  severe  consequences  arising  from  an  infected  implanted  pacemaker  or
defibrillator and the data available there should be no discussion on the use of  preven‐
tive perioperative antibiotics. Randomized data were reported only on the use of a single
shot  cephfazolin  although some other  antibiotic  agents  are  supposed to  be  equally  effi‐
cient as almost every perioperative device infection is caused by staphylococci or strepto‐
cocci.  In  some  hospitals  with  a  high  rate  of  methicillin  resistant  staphylococci
vancomycin may be the most proper choice.  There is  an interesting new approach with
coated devices that needs further evaluation.
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